Clinical trial · Observational
Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging
NCT02203136CI-TRIAL-00038760completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this research study is to improve detection of cancer outside of the bladder through genetic testing and improved imaging.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Magnetic Resonance Imaging (MRI) | Procedure | — | UNRESOLVED |
| Tissue Biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Muscle Invasive Bladder Cancer (MIBC)
- description
- During bladder cancer surgery, whole genome gene expression array assays obtained on tumor biopsy specimens. Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC. 3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
- interventionNames
- Procedure: Tissue Biopsy
- Procedure: Magnetic Resonance Imaging (MRI)
Primary outcomes (1)
- measure
- Detection Improvement of Cancer Outside of the Bladder
- timeFrame
- 4 weeks
- description
- Improved cross sectional imaging with pelvic MRI, and biopsy specimen molecular profiling used to identify muscle invasive bladder cancer (noc-MIBC). Analysis to determine biologic subtypes which will then be correlated with final pathology, identifying the subtype(s) associated with noc-MIBC.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: 1\. Patients with biopsy proven bladder cancer of any age will be eligible for enrollment. Exclusion Criteria: 1. Contraindication to pelvic MRI (metallic implants/hardware, claustrophobia) 2. Participants who have previously received chemotherapy as part of multimodal therapy.
References
Publications (0)
Data not yet available
No reference posted for this study.